Collin Van Ryn

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 268 citations · Full text

Cog Anbl1221, Neuro-oncology, Glioma +4

Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma

Daniel von Allmen, Andrew M. Davidoff, Wendy B. London et al. · Journal of Clinical Oncology · 2017 · 167 citations

Surgical Oncology, Cancer Management, Interdisciplinary Neurosurgery +25

Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

Kevin Campbell, Julie M. Gastier‐Foster, Meegan Mann et al. · Cancer · 2017 · 137 citations · Full text

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Maged Zeineldin, Sara M. Federico, Xiang Chen et al. · Nature Communications · 2020 · 115 citations · Full text

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study

Rochelle Bagatell, Kieran McHugh, Arlene Naranjo et al. · Journal of Clinical Oncology · 2016 · 55 citations · Full text